3 267

Cited 5 times in

Influence of boost radiotherapy in patients with ductal carcinoma in situ breast cancer: a multicenter, retrospective study in Korea (KROG 11-04)

Authors
 Jin Hee Kim  ;  Doo Ho Choi  ;  Won Park  ;  Seung Do Ahn  ;  Su Ssan Kim  ;  Sung Whan Ha  ;  Kyubo Kim  ;  Yong Bae Kim  ;  Ji Woon Yea  ;  Min Kyu Kang  ;  Kyung Hwan Shin  ;  Dong Won Kim  ;  Ji Hae Lee  ;  Chang-Ok Suh 
Citation
 BREAST CANCER RESEARCH AND TREATMENT, Vol.146(2) : 341-345, 2014 
Journal Title
 BREAST CANCER RESEARCH AND TREATMENT 
ISSN
 0167-6806 
Issue Date
2014
MeSH
Breast Neoplasms/mortality ; Breast Neoplasms/pathology* ; Breast Neoplasms/radiotherapy* ; Carcinoma, Intraductal, Noninfiltrating/mortality ; Carcinoma, Intraductal, Noninfiltrating/pathology* ; Carcinoma, Intraductal, Noninfiltrating/radiotherapy* ; Female ; Humans ; Neoplasm Grading ; Neoplasm Recurrence, Local ; Radiotherapy, Adjuvant ; Republic of Korea ; Retrospective Studies ; Risk Factors ; Treatment Outcome
Keywords
Breast cancer ; Ductal carcinoma in situ ; Radiation therapy ; Boost ; HER2
Abstract
To estimate the effect of boost radiotherapy on local recurrence-free survival (LRFS) in patients with ductal carcinoma in situ (DCIS) breast cancer. We included patients from nine institutions who met the following criteria: having Tis, age 18 years or older, having breast conserving surgery (BCS) and radiotherapy within 12 weeks after surgery. From 1995 through 2006, 728 patients were analyzed retrospectively by the Korean Radiation Oncology Group. All patients received whole-breast radiation therapy (WBRT) after BCS. 232 patients (31.9 %) also received boost radiation therapy (RT) (median 10 Gy). After median follow-up of 82 months, 5-year LRFS was 98.4 % and 10-year LRFS was 95.8 % for all patients. There was no statistically significant difference of LRFS between the boost and no-boost groups. Nineteen (2.6 %) patients had ipsilateral breast recurrences, including 12 of invasive recurrence and 7 DCIS. The presence of the HER2 receptor was associated with more invasive recurrences. Nine (1.2 %) patients developed contralateral breast cancer, including six invasive breast cancer and three DCIS. In the multivariate analysis, only the margin status was a significant prognostic factor for LRFS. Boost RT was not associated with further improvement of local control in DCIS after BCS and WBRT. HER2 receptor-positive patients may need further treatment with the anti-HER2 agents.
Full Text
http://link.springer.com/article/10.1007%2Fs10549-014-3025-4
DOI
10.1007/s10549-014-3025-4
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Kim, Yong Bae(김용배) ORCID logo https://orcid.org/0000-0001-7573-6862
Suh, Chang Ok(서창옥)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/100101
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse